Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.

Journal of hematology & oncology - 13 Jun 2017

Wen Jianguo, Tao Wenjing, Hao Suyang, Zu Youli

Abstract excerpt

BACKGROUND: Sickle cell disease (SCD) is a disorder of red blood cells (RBCs) expressing abnormal hemoglobin-S (HbS) due to genetic inheritance of homologous HbS gene. However, people with the sickle cell trait (SCT) carry a single allele of HbS and do not usually suffer from SCD symptoms, thus providing a rationale to treat SCD. METHODS: To validate gene therapy potential, hematopoietic stem cells were isolated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Antigens, CD34

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clustered Regularly Interspaced Short Palindromic Repeats

Share to Erythroid Cells

Share to Erythropoiesis

Share to Hemoglobin, Sickle

Share to Hemoglobins

Share to Sickle Cell Trait

Source

Open in PubMed Open full text

Identifiers

PMID: 28610635
DOI: 10.1186/s13045-017-0489-9
PMCID: PMC5470227

Genes

SCD
SCT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.PMID 28610635Read ↗

Efficient Correction of the Sickle Mutation in Human Hematopoietic Stem Cells Using a Cas9 Ribonucleoprotein ComplexSemantic proximity Read ↗

Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell diseaseSemantic proximity Read ↗

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 <sup>+</sup> cell therapy to induce fetal hemoglobin for sickle cell diseaseSemantic proximity Read ↗

Genome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside.Semantic proximity Read ↗

Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.Semantic proximity Read ↗

Sickle cell disease: understanding pathophysiology, clinical features and advances in gene therapy approachesSemantic proximity Read ↗

CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell diseaseSemantic proximity Read ↗

Clinical genome editing to treat sickle cell disease—A brief updateSemantic proximity Read ↗

CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell DiseaseSemantic proximity Read ↗

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell diseaseSemantic proximity Read ↗

Gene Therapy of HemoglobinopathiesSemantic proximity Read ↗

Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.